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Introduction
Background
Atrial fibrillation (AF) is the most common ar-
rhythmia seen in clinical practice and has several 
unfavorable implications, mostly systemic and 
cerebral embolism, reduced cardiac output and 
death.1-3 Symptoms related to AF include palpi-
tations due to irregularities in the heart rate, and 
hemodynamic impairment due to reduced stroke 
volume related to the loss of atrial contribution to 
ventricular filling. The cornerstones of the manage-
ment of AF are treatment of symptoms related to 
irregular heart rhythm and reduced stroke volume 
as well as thromboembolism prophylaxis. While 
rhythm and rate control are considered equivalent 
in terms of long-term clinical end points,4,5 main-
tenance of sinus rhythm is sought in highly symp-
tomatic patients. Pharmacologic therapies have 
been used for rhythm control but can be associ-
ated with long-term side effects as well as clinical 
failure. Other approaches include atrioventricular 
junction ablation, surgical or percutaneous radio 
frequency ablation, as well as device therapies 
such as atrial defibrillators (ADs). The latter were 
developed and approved before left atrial ablation 
became widely available. The purpose of this ar-
ticle is to describe the role of ADs in the current 
armamentarium of AF therapies. 
Corresponding Address: Deepak Bhakta MD FACC FAHA FHRS, Krannert Institute of Cardiology, 1800 N. Capitol Avenue, 
Indianapolis, Indiana 46202 U.S.A.
Is An Atrial Defibrillator Still An Option In 
Treating Patients With Atrial Fibrillation?
Ziad El Khoury MD and Deepak Bhakta MD FACP FACC FAHA FHRS
Krannert Institute of Cardiology, Indiana University School of Medicine, Indiana University Health Physicians.
Abstract
Atrial fibrillation (AF) is a common disorder associated with significant morbidities and presents several 
challenges for the control of symptoms and prevention of long-term implications. Atrial defibrillators 
(ADs), used for rhythm control in patients with symptoms refractory to medical therapy, can detect re-
currences of the arrhythmia, allow prompt patient-directed treatment, and have the potential to reduce 
hospitalizations and improve quality of life. The efficacy of this form of therapy is highest in patients 
with paroxysmal AF, and with the use of a coronary sinus shocking lead. While R-wave synchronized 
shocks are a prerequisite for a safe use, the procedure is well tolerated and usually not associated with 
long-term psychological side effects. Limitations of ADs include acute and chronic complications related 
to cardiac rhythm device implantation, the requirement in some cases for more than one shock to termi-
nate AF, the discomfort from shocks, as well as the need for sedation to alleviate pain from the shocks. 
With the ever-expanding role of catheter-based therapies for AF, it seems that the role of ADs in this 
regard is rather limited.
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Indication, Description of the Implantation 
Procedure and the ADs Systems 
Candidate patients for the implantation of an 
atrial defibrillator are those with recurrent symp-
tomatic atrial fibrillation who have failed phar-
macologic therapy.6 Other selection criteria ex-
ist as well, such as an acceptable number of AF 
episodes that would warrant implanting a per-
manent device, but without excessive burden re-
sulting in repetitive therapies. An atrial defibril-
lator includes one or two coils in the atria and a 
ventricular lead for sensing and synchronization 
purposes. In most cases, this requires cannula-
tion of the coronary sinus, adding another layer 
of complexity to the implantation procedure. In 
simpler configurations, standard single or dual 
chamber ventricular defibrillators have been used 
for atrial defibrillation purposes. In such systems, 
the shock vector configuration between the ventri-
cle and the pectoral ICD usually includes the atria 
and therefore, successfully terminates atrial fibril-
lation. While original studies suggested that such 
devices have the drawback of relatively higher 
defibrillation thresholds, more recent ones did not 
find a particular advantage to CS shocking leads. 
7,8 This approach is particularly appealing since 
it can be used in patients who could not receive 
a coronary sinus lead for technical reasons, and 
would open the door for using standard ICDs for 
cardioversion given the high incidence of atrial fi-
brillation in patients with such systems. Patients 
with heart failure who receive ventricular defibril-
lators with or without resynchronization therapy 
may be candidates as well for atrial defibrilla-
tors, were devices with both capacities available. 
Several generations of ADs were commercially 
available. Metrix (Incontrol – Redmond, WA) was 
the first such device to be developed, and had 
shocking leads in the right atrium and the coro-
nary sinus.10 Subsequent generations of ADs such 
as Jewel AF and GEM III AT (Medtronic – Minne-
apolis, MN) had additional features. Compared to 
the Metrix Activator, Jewel AF was a dual cham-
ber defibrillator capable of ventricular defibril-
lation, and had the advantages of greater pro-
grammability and superior diagnostic abilities, 
with a patient activator for rhythm confirmation 
and shock delivery capabilities [Figure 1]. On the 
other hand, GEM III AT was a dual chamber defi-
brillator that shared many of the features of Jewel 
AF, but did not include a coronary sinus lead. 
Efficacy
While electrical cardioversion of atrial fibrillation 
is usually performed by applying energy across the 
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Figure 1: Medtronic Jewel AF Atrial Defibrillator and Patient Activator 32 (with Permission)
chest, endocardial leads can be used to terminate 
AF, with some evidence suggesting that it is effec-
tive in patients who fail external cardioversion.11  
It is also well known that patients with ventricular 
defibrillators receive inappropriate shocks due to 
rapidly conducted AF, and multi-programmable 
dual chamber ICDs can discriminate between su-
praventricular and ventricular tachycardia and 
terminate AF by pacing.12 The efficacy of using 
low-energy atrial cardioversion has been evalu-
ated in several studies that included patients with 
persistent or paroxysmal AF, as well as those with 
structural heart disease and reduced left ventricu-
lar function.13 When studied in the electrophysi-
ology lab, the success rate of conversion to sinus 
rhythm is 70% in cases of persistent AF, and up to 
90% with paroxysmal AF, using catheters in the 
right atrium and either the coronary sinus or the 
branch pulmonary artery.14,15 The recurrence rate, 
on the other hand, is not minimal and can be as 
high as 37% over an average follow up period of 
9 months. Energy requirements for successful car-
dioversion differ among the different subsets of 
AF, ranging from 1.8 J for paroxysmal AF to 3.6 J 
for persistent AF.15  Other factors that are associat-
ed with lower energy requirements include short-
er duration of AF, smaller left atrial size, absence 
of structural heart disease, higher left ventricular 
ejection fraction, and smaller left ventricular cav-
ity dimensions.14,15 Delivering sequential biphasic 
waveforms over dual-current pathways can lead 
to lower defibrillation threshold as well.16 
Using ADs to deliver R-wave synchronized 
shocks as a long-term treatment strategy for re-
current drug-refractory AF is successful in 90-95% 
of cases .17 Approximately 27% of episodes re-
quire more than one shock, and an average of 1.6 
shocks is needed per episode for termination.10,17 
Determinants of first-shock success are the use of 
a coronary sinus electrode, absence of a class III 
anti-arrhythmic drug, and the absence of early re-
currence of AF.18 It is notable that early cardiover-
sion (within 3 hours of onset of AF) was a nega-
tive determinant of first shock success in some 
studies,18 but when taking into account episodes 
that have lasted for weeks, the longer the waiting 
time, the higher the required energy for success-
ful cardioversion.19 Atrial anti-tachycardia pacing 
is generally considered a poor strategy to termi-
nate atrial fibrillation, with the GEM III AT ICD 
able to terminate AF in only 26% of cases.20  50 Hz 
atrial burst pacing does not seem to add much ad-
ditional benefit with success rates of 25-30%, and 
a worse result if the atrial cycle length is less than 
160 ms.
Terminating AF with these devices translated 
into an improvement in symptoms, quality of life 
and ability to perform physical activities, as well 
as a reduction in arrhythmia-related hospitaliza-
tions.21
Safety
From a safety standpoint, ventricular arrhyth-
mias are rarely induced when shocks are synchro-
nized, even in patients with history of ventricular 
tachycardia and left ventricular dysfunction. Rare 
episodes of ventricular fibrillation (VF) have been 
induced in cases of T wave oversensing, shock ad-
ministration during ventricular-paced rhythm or 
ventricular tachycardia (VT). Cardioversion of AF 
using low-energy R-wave synchronized shocks is 
therefore considered safe, if delivered during nar-
row-complex rhythm, even in patients with his-
tory of VT.17,22  One other potential safety concern 
is the development of post-shock bradycardia in 
up to one third of patients.Since these devices are 
capable of dual chamber pacing, this issue poses 
minor clinical consequence.
Benefits and Limitations
In addition to symptom control, advantages of 
implanted ADs are the ability to perform cardio-
version in the outpatient setting, at a time that is 
socially and physically acceptable, and possibly 
without the direct involvement of a health care 
professional. Thus, it avoids hospitalization, em-
powers patients to control atrial fibrillation symp-
toms, and allows for their direct participation in 
the health delivery process. The projected effects 
are improvement in quality of life and health care 
savings. 
On the other hand, implanted devices can have 
specific disadvantages that can be divided into 
immediate and long-term limitations. Immediate 
disadvantages include infection and mechanical 
complications from the implantation procedure 
such as pneumothorax, cardiac perforation and 
tamponade. The rate of such complications can 
be as high as 4%.17 In the long term, there is the 
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possibility of inappropriate shocks, the discom-
fort from appropriate discharges, and vascular 
complications such as venous occlusion. Clinic 
visits are also required on a regular basis for de-
vice monitoring and management. It should also 
be noted that appropriate anticoagulation must 
be maintained at all times since cardioversion can 
be performed at any moment, and theoretically 
should be stricter than in the general population 
of patients with atrial fibrillation. Not all patients 
receiving atrial defibrillators for recurrent, symp-
tomatic and drug-refractory AF can be transi-
tioned to an ambulatory delivery of shocks and 
most patients do not become free of anti-arrhyth-
mic medications.17 
Other limitations include shock failures, AF 
storms leading to repetitive shocks, unexpected 
shocks if the device is programmed to automati-
cally treat AF, treating asymptomatic episodes 
(asymptomatic AF burden may be as high as 10-
fold compared to symptomatic episodes), inap-
propriate diagnosis of ventricular arrhythmias 
due to far-field R wave sensing or misclassifica-
tion of rapidly conducted AF as ventricular fibril-
lation. 
The long-term psychological and physical effects 
are applicable to any implantable device and in-
clude physical concerns, driving restrictions, 
over-protectiveness from family, requirement for 
generator changes, and potential for device mal-
function and recalls. It has been estimated that 
many patients who receive ventricular defibrilla-
tors develop symptoms of anxiety and depression 
post implantation.While this has not been shown 
in patients with atrial defibrillators and no cor-
relation was seen between shock frequency and 
development of anxiety, this could be due to the 
relatively smaller number of patients studied and 
may also be related to the fact that ICD shocks are 
less predictable and are used to treat life-threaten-
ing arrhythmias. 
The efficacy of beta-adrenergic blocking agents 
for rate control in AF and maintenance of sinus 
rhythm after cardioversion is well-established.17,18 
However, their role in the primary prevention 
of AF is less defined. Maladaptive adrenergic 
stimulation is postulated to contribute to the 
electrophysiologic and structural atrial remodel-
ing mechanisms that initiate and perpetuate AF. 
Blunting this excessive sympathetic response, in 
theory, may help prevent the development of this 
disease.
Tolerability and Means to Improve it
Pain perception is one of the main factors that af-
fect the widespread use of the atrial defibrillator. 
The type of pain that patients perceive is described 
as a dull sensation in the anterior chest that is rela-
tively short-lived, typically disappearing within 
30 seconds.9  Pain level usually correlates with in-
creasing voltage, with marked inter-individual 
variation.14,23 It is unusual that sinus rhythm is re-
stored before the tolerability threshold is reached. 
In one study, the average discomfort score was 
5.2 on a 1-10 scale for successful therapy, and was 
slightly lower for unsuccessful therapy. As expect-
ed, satisfaction score was much higher for success-
ful therapy.10 The vast majority of patients perceive 
shocks of 3J or more to be intolerable.24 In a differ-
ent study, patients were usually unable to distin-
guish between shocks of 0.4 to 2 J and perceived 
the shocks as uncomfortable and rated the second 
shock as more painful irrespective of the actual en-
ergy level. Still, more than 80% of patients mention 
that they would tolerate such shocks at a rate of 
one per month and around 45% felt a weekly shock 
is acceptable. This implies that patients are willing 
to accept the shocks for symptomatic treatment as 
long as the number of shocks needed to terminate 
each episode is minimized and the discharges are 
infrequent.25  In the majority of cases however, only 
few patients tolerate internal cardioversion while 
fully conscious.23
Since pain perception is a major impediment, 
achieving an atrial defibrillation threshold that 
is lower than the discomfort threshold is of para-
mount importance.Unfortunately, this is rarely 
feasible. In many instances, it has been shown that 
the comfort threshold is 0.1 joules or more, which 
is considerably lower than the atrial defibrillation 
threshold of implanted devices.To alleviate this 
burden, adjunctive therapies such as antiarrhyth-
mic medications to decrease the defibrillation 
threshold, manual controllers for self-administra-
tion of shocks, programming nocturnal therapies 
or even using self administered premedication may 
be needed, each approach with its own limitations. 
Automatic nighttime cardioversion has been shown 
to be effective and is generally well tolerated, but 
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Impact on Quality of life (QOL)
When the quality of life of patients with drug 
refractory symptomatic AF who receive ADs is 
followed over time, the baseline score is usually 
reduced compared to the general population, 
but all components of the questionnaire improve 
with time. The benefit seems to affect all patients, 
irrespective of whether they actually received 
shocks during the follow up period. While this 
implies a partial placebo effect, the shocks do 
not negate any improvement in the QOL.32  Lev-
els of anxiety and depression do not worsen and 
most patients mention that they would have the 
device implanted again.33 When spouses and 
partners are asked, they do not have specific un-
favorable opinions about the devices either.34
Conclusions
With newer anti-arrhythmic drugs enhancing 
safety and efficacy, and ablation becoming widely 
accepted, it is unlikely that the use of ADs will 
increase.The need for permanent device im-
plantation has been less attractive, particularly 
in younger patients, due to long-term consider-
ations such as chronic risk of infection, vascular 
complications, device longevity, and avoidance 
of magnetic resonance imaging. These issues are 
more acceptable with ventricular-based ICDs 
given the life-saving potential of such devices; 
atrial-specific defibrillators lack this benefit. Evi-
dence comparing outpatient cardioversion versus 
ADs is lacking, and cost, convenience, and patient 
acceptance would need to be directly compared, 
but this is unlikely to happen. The 2011 ACCF/
AHA/HRS guidelines for the treatment of atrial 
fibrillation do not present a specific set of recom-
mendations for their use, and acknowledge that 
only a small subset of patients may benefit from 
them.36 In our opinion, ADs may have a specific 
role in those with recalcitrant, paroxysmal AF 
where other treatment strategies have failed, and 
in those who are willing to undergo unsedated, 
self-administered cardioversion. Given that a 
very small population would derive benefit from 
ADs, it is uncertain if manufacturers would con-
tinue to offer such therapy in their future prod-
uct lines. The most feasible approach would be 
to incorporate ADs in standard ICDs or cardiac 
resynchronization devices, though this may be 
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many patients are not suitable for this strategy 
because of their irregular sleep habits with some 
who qualify remaining awake when the shock 
is administered; for some, the sleep pattern may 
become disrupted.26 While nocturnal cardiover-
sion may decrease the anxiety associated with the 
shocks, the pain perception is usually the same. 
Sedation is required to prevent the pain and dis-
comfort associated with shock delivery,especially 
in patients who are expected to receive frequent 
cardioversions, and in those where therapies are 
administered automatically rather than by patient 
activation. Among the medications tried, the best 
approach includes a benzodiazepine, possibly 
combined with an analgesic. In that regard, orally 
administered midazolam has been shown to be 
the most effective due to of its amnestic effect. An 
analgesia only strategy usually fares worse com-
pared to sedation.27 Knowing that the success of 
atrial defibrillation becomes markedly reduced 
with repeated cardioversions, and that high-en-
ergy requirements might preclude patients with 
long-lasting AF from receiving ADs, anti-arrhyth-
mics have been used to lower the atrial defibril-
lation threshold and decrease pain perception. 
Both flecainide and sotalol have been evaluated in 
such settings. Intravenous flecainide significantly 
decreases the energy requirement and improves 
the chance of successful cardioversion in patients 
with AF, irrespective of the subtype.This trans-
lates into a significant reduction in pain scores in 
patients not using sedation28 Sotalol may play a 
role as well in improving the chances of maintain-
ing sinus rhythm after cardioversion. As many as 
30% of patients with persistent atrial fibrillation 
have very early recurrence after cardioversion, 
and more shocks and higher energy delivery do 
not decrease the recurrence rate. Therefore, us-
ing medications to decrease this rate is an attrac-
tive approach. Since recurrent atrial fibrillation is 
triggered by premature atrial contractions (PACs) 
in the vast majority of cases, intravenous sotalol 
has been shown to decrease the number of PACs, 
prolong their coupling interval and prevent early 
recurrence in 83% of patients.19,29-31 In addition, 
when sotalol is used after cardioversion of atrial 
fibrillation, the mean defibrillation threshold is 
decreased from 6.7 to 3.8 J using the same lead 
configuration. This translates into a lower seda-
tive dose with the second procedure, as well as 
lower average pain score (5.1 vs. 2.7 on scale of 0 
to 10).19
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what some would consider a prohibitively expen-
sive approach. Despite these limitations, research 
in this field remains active.37-40 Consideration for 
future therapies may include devices directed 
towards more tolerable therapy such as those of-
fering superior shock waveforms (allowing lower 
shock energy/voltage) or novel pacing strategies 
to effectively suppress AF triggers. Such innova-
tions may ultimately allow for a revival of these 
devices.
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